Soleno Therapeutics Inc
SLNO
Company Profile
Business description
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.
Contact
100 Marine Parkway
Suite 400
Redwood CityCA94065
USAT: +1 650 213-8444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
182
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,983.30 | 42.10 | -0.47% |
| CAC 40 | 8,227.32 | 70.89 | 0.87% |
| DAX 40 | 24,155.45 | 39.45 | -0.16% |
| Dow JONES (US) | 49,310.32 | 179.71 | -0.36% |
| FTSE 100 | 10,457.01 | 19.45 | -0.19% |
| HKSE | 25,862.61 | 52.59 | -0.20% |
| NASDAQ | 24,438.50 | 219.06 | -0.89% |
| Nikkei 225 | 59,523.69 | 383.46 | 0.65% |
| NZX 50 Index | 12,870.33 | 14.60 | -0.11% |
| S&P 500 | 7,108.40 | 29.50 | -0.41% |
| S&P/ASX 200 | 8,762.80 | 35.80 | -0.41% |
| SSE Composite Index | 4,069.37 | 23.88 | -0.58% |